Results 11 to 20 of about 2,141 (187)

Off-Label Uses of Abrocitinib: Review of Emerging Therapeutic Applications beyond Atopic Dermatitis

Life
Abrocitinib, an oral small-molecule Janus Kinase 1 (JAK1) inhibitor, is primarily approved for treating moderate-to-severe atopic dermatitis (AD) in adults and adolescents aged 12 and older. This review examines the emerging off-label uses of Abrocitinib.
George Mitroi, Mihaela Roxana Mitroi
exaly   +4 more sources

Effect of abrocitinib and dupilumab on eosinophil levels in patients with moderate‐to‐severe atopic dermatitis [PDF]

JEADV Clinical Practice, 2023
Background Eosinophilia is common in patients with atopic dermatitis (AD). Abrocitinib, an oral Janus kinase‐1 inhibitor and dupilumab, an anti–interleukin‐4 receptor‐α antibody, are approved for moderate‐to‐severe AD.
Delphine Staumont‐Sallé, Sébastien Barbarot, Jean David Bouaziz, Chan Chan, Claire Clibborn, Aurélie Du‐Thanh, Claire Feeney, Alexandre Lejeune, Laurent Misery, Audrey Nosbaum, Julien Seneschal, Angèle Soria, Fan Zhang   +12 more
doaj   +2 more sources

Abrocitinib: First Approval

Drugs, 2021
Abrocitinib (Cibinqo®) is an oral small-molecule inhibitor of Janus kinase 1 (JAK1) being developed by Pfizer for the treatment of moderate-to-severe atopic dermatitis (AD). In September 2021, abrocitinib was approved in the UK and Japan for the treatment of moderate-to-severe AD in adults and adolescents 12 years and older who are candidates for ...
Deeks, Emma D., Duggan, Sean
openaire   +3 more sources

JAK1 inhibition with abrocitinib decreases allergen-specific basophil and T-cell activation in pediatric peanut allergy

Journal of Allergy and Clinical Immunology: Global, 2023
Background: JAK1 is a signaling molecule downstream of cytokine receptors, including IL-4 receptor α. Abrocitinib is an oral JAK1 inhibitor; it is a safe and effective US Food and Drug Administration–approved treatment for adults with moderate-to-severe ...
Nicole Ramsey, MD, PhD, Wajiha Kazmi, BS, Matthew Phelan, BA, Daniel Lozano-Ojalvo, PhD, M. Cecilia Berin, PhD   +4 more
doaj   +2 more sources

Abrocitinib versus Placebo or Dupilumab for Atopic Dermatitis [PDF]

New England Journal of Medicine, 2021
The oral Janus kinase 1 (JAK1) inhibitor abrocitinib, which reduces interleukin-4 and interleukin-13 signaling, is being investigated for the treatment of atopic dermatitis. Data from trials comparing JAK1 inhibitors with monoclonal antibodies, such as dupilumab, that block interleukin-4 receptors are limited.In a phase 3, double-blind trial, we ...
Bieber, T, Simpson, EL, Silverberg, JI, Thaci, D, Paul, C, Pink, AE, Kataoka, Y, Chu, C-Y, DiBonaventura, M, Rojo, R, Antinew, J, Ionita, I, Sinclair, R, Forman, S, Zdybski, J, Biswas, P, Malhotra, B, Zhang, F, Valdez, H   +18 more
openaire   +5 more sources

Practical Management of the JAK1 Inhibitor Abrocitinib for Atopic Dermatitis in Clinical Practice: Special Safety Considerations [PDF]

Dermatology and Therapy
Abrocitinib, an oral, once-daily, Janus kinase (JAK) 1-selective inhibitor, is approved for the treatment of adults and adolescents with moderate-to-severe atopic dermatitis (AD). Abrocitinib has shown rapid and sustained efficacy in phase 3 trials and a
Melinda J. Gooderham, Marjolein de Bruin-Weller, Stephan Weidinger, Michael J. Cork, Lawrence F. Eichenfield, Eric L. Simpson, Athanasios Tsianakas, Urs Kerkmann, Claire Feeney, William Romero   +9 more
doaj   +4 more sources

Efficacy and safety of abrocitinib for moderate-to-severe atopic dermatitis in adolescents and adults: Meta-analysis [PDF]

Frontiers in Pharmacology, 2023
Objective: This study aims to investigate the safety and efficacy of abrocitinib in treating moderate-to-severe AD in adolescents and adults.Methods: Pubmed, Cochrane, Embase, and Web of science data base were searched from inception to 9 August 2022 ...
Ling Li, Jiajun Yu, Baoqing Chen, Ying Guo, Yufeng Yang   +4 more
doaj   +2 more sources

Effectiveness and safety of methylprednisolone combination with abrocitinib compared to methylprednisolone combination with azathioprine in bullous pemphigoid: a retrospective study

Scientific Reports
Bullous pemphigoid (BP) is an autoimmune skin disorder involving Th2-related inflammation. Abrocitinib is a JAK1 inhibitor and a promising therapeutic option for BP as it can effectively attenuate Th2-associated inflammation.
Ying Chen, Zheyu Zhuang, Jing Mao, Siyi Bao, Yihua Zhang, Zhenlan Wu, Wenyun Chen, Zequn Tong, Ting Gong, Chao Ji   +9 more
doaj   +2 more sources

Oral abrocitinib in the treatment of granuloma annulare: a case report

Journal of Dermatological Treatment
Aim: To evaluate the therapeutic efficacy and safety of JAK inhibitor abrocitinib in patients with localized granuloma annulare (GA) and to review the available cases documented in English.Methods: We presented a patient who had a persistent, localized ...
Jingyao Liang, Xibao Zhang
exaly   +3 more sources

Effect of Abrocitinib on the Skin Microbiome in Patients With Moderate‐to‐Severe Atopic Dermatitis

Allergy, EarlyView.
Atopic dermatitis (AD) is characterized by microbial dysbiosis. This study aimed to evaluate the effects of abrocitinib, a JAK1‐selective inhibitor, on the skin microbiome and its potential associations with clinical outcomes in patients with AD. Abrocitinib treatment was associated with increased skin microbial diversity and decreased Staphylococcus ...
Madeline Kim, Ester Del Duca, Joel Correa Da Rosa, Juliana Pulsinelli, Yeriel Estrada, Dan Xu, Gary Chan, Allshine Chen, Erman Güler, Karen Page, Emma Guttman‐Yassky   +10 more
wiley   +2 more sources